Vaccines and autoimmunity during the COVID-19 pandemic

doi:10.5411/wji.v12.i2.9

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 2

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8856)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

334

WORD

HTML

3006

Figures (1-1)

724

Sum=4152

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

568

Download

1910

Sum=2478

Publishing Process of This Article

Item

Count

Browse

665

Download

1556

Sum=2221

Aug 24, 2022 (publication date) through Feb 17, 2026

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Immunology

ISSN

2219-2824

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Editorial

World J Immunol. Aug 24, 2022; 12(2): 9-14
Published online Aug 24, 2022. doi: 10.5411/wji.v12.i2.9

Vaccines and autoimmunity during the COVID-19 pandemic

Tsvetelina Velikova

Tsvetelina Velikova, Department of Clinical Immunology, University Hospital Lozenetz, Sofia 1407, Bulgaria

Tsvetelina Velikova, Medical Faculty, Sofia University, Sofia 1407, Bulgaria

Author contributions: Velikova T wrote the draft and revised the final version.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Corresponding author: Tsvetelina Velikova, MD, PhD, Assistant Professor, Department of Clinical Immunology, University Hospital Lozenetz, Kozyak 1 Street, Sofia 1407, Bulgaria. tsvelikova@medfac.mu-sofia.bg

Received: July 2, 2021
Peer-review started: July 2, 2021
First decision: July 30, 2021
Revised: August 13, 2021
Accepted: July 24, 2022
Article in press: July 24, 2022
Published online: August 24, 2022
Processing time: 416 Days and 6.4 Hours

Core Tip

Core Tip: Coronavirus disease 2019 (COVID-19) vaccines have created concerns about their efficacy and safety, notably in autoimmune patients. Which vaccine adverse events are related to the underlying autoimmunity is unclear. Additional data is needed to evaluate the immunological impact of COVID-19 vaccines in terms of effectiveness and immune-driven adverse effects that might provoke a disease flare in individuals with a history of autoimmune-related symptoms. However, the risk of autoimmune disease flare after vaccination was considered low, while the immune responses after vaccination showed great immunogenicity for these patients. In addition, vaccination will considerably decrease related morbidity and mortality from COVID-19 in autoimmune patients.